SAB Biotherapeutics- Warrants (25/07/2027) EBIT

The latest EBIT for SABSW is $-120M as of March 2026. That compares with $-33M in the prior-year period — down 268.9% year over year. That is below the sector sector average of $-69M. Investors often review this figure alongside SAB Biotherapeutics- Warrants (25/07/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SABSW's EBIT moved from $-33M to $-120M — a 268.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics- Warrants (25/07/2027)'s operating scale or balance-sheet position.

Against its sector companies, SABSW currently prints $-120M for EBIT, while the sector average sits near $-69M. That is roughly 76.3% below the sector mean. Large gaps often invite a closer look at SAB Biotherapeutics- Warrants (25/07/2027)'s growth, margins, and balance sheet.

A EBIT figure of $-120M for SABSW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting SABSW's EBIT ($-120M), review year-over-year change from $-33M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.